#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians caring for pregnant and postpartum people with HIV need to understand that substance use patterns shift dramatically in the postpartum period, with alcohol use rising more than fivefold, requiring targeted screening and intervention strategies tailored to this vulnerable population. Identifying distinct risk factors for alcohol versus cannabis use enables more precise clinical counseling about teratogenic and neurodevelopmental risks during pregnancy and potential impacts on medication adherence and viral suppression in both pregnant and postpartum periods. This evidence supports the need for integrated prenatal and postpartum care protocols that address concurrent HIV management, mental health, and substance use to optimize outcomes for both parent and child.
This study examined alcohol and cannabis use patterns among pregnant and postpartum people with HIV, finding a striking increase in alcohol use from 8% during pregnancy to 44% postpartum, while identifying distinct psychosocial risk factors for each substance. The research highlights that alcohol and cannabis use in this population are driven by different underlying factors, with implications for tailored clinical interventions during the vulnerable postpartum period. For clinicians managing pregnant and postpartum patients with HIV, understanding these substance use trajectories is critical because both alcohol and cannabis can affect antiretroviral adherence, vertical transmission prevention, and maternal-infant bonding. The postpartum spike in alcohol use suggests that pregnancy-related behavioral motivation may diminish after delivery, necessitating proactive screening and support strategies in the immediate postpartum period. Clinicians should implement substance-specific counseling during prenatal visits and plan enhanced postpartum monitoring and psychosocial support to address the documented increase in alcohol use at this transition point.
“This observational data raises a legitimate clinical flag about postpartum vulnerability in this population, though we should be careful about drawing causal conclusions from the study design. What’s clinically important is that we’re identifying a window where substance use risk escalates significantly, which means our prenatal counseling and postpartum support protocols for people with HIV need to address this specific transition period.”
💊 Clinicians caring for pregnant and postpartum people with HIV should recognize that substance use patterns shift significantly across the perinatal period, with alcohol use rising substantially after delivery—a finding that suggests distinct motivations and risk pathways for alcohol versus cannabis that warrant individualized assessment. The identification of different risk factors for each substance indicates that a one-size-fits-all harm reduction approach will likely miss critical intervention opportunities, particularly given the intersecting health vulnerabilities of this population managing both HIV and pregnancy-related complications. Important caveats include the relatively small sample sizes typical of such studies, potential underreporting bias given stigma around substance use in pregnancy, and limited data on dose, frequency, and actual harms in this specific group. Clinicians should proactively inquire about both alcohol and cannabis use at multiple prenatal and postpartum visits, recognizing postpartum as a period of heightened risk, while coordinating care with addiction
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
